Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms that the Annual Report and Accounts for the year ended 31 December 2021 ("2021 Annual Report") and the Notice of the 2022 Annual General Meeting ("AGM") have now been published on the Company's website: https://vericidx.com/investors/.
The 2021 Annual Report, the Notice of AGM and details for voting by proxy will be posted to shareholders who have not consented to receive electronic communications today, on 25 May 2022.
The AGM is to be held at 3:00pm on 27 June 2022 at the Company’s registered offices, at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ and will consider the Resolutions set out in the Notice of AGM.
The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 3:00pm on 24 June 2022. To register for dial-in details and to submit any questions please contact Walbrook PR via email at email@example.com or call +44 (0)20 7933 8780.
Shareholders will not receive a hard copy form of proxy for the 2022 AGM in the post. Instead, Shareholders will be able to vote electronically using the link www.signalshares.com. Proxy votes must be received no later than 3:00pm on 23 June 2022.
Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales. Alternatively, shareholders can vote by downloading the new app, LinkVote+, on Apple App Store or Google Play and follow the instructions.
Sara Barrington, CEO
Julian Baines, Chairman
|N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
|Tel: 020 7496 3000|
|Walbrook PR Limited
Paul McManus / Sam Allen
Tel: 020 7933 8780 or firstname.lastname@example.org
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.